Literature DB >> 24967890

Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway.

Nancy Turner1, Leticia Nolasco1, Jennifer Nolasco1, Sarah Sartain1, Joel Moake1.   

Abstract

Molecular linkages between von Willebrand factor (VWF) and the alternative complement pathway (AP) have recently been discovered. Endothelial cell (EC)-anchored ultra-large (UL) VWF multimeric strings function as an activating surface for the AP. C3 (in active C3b form) binds to the EC-anchored ULVWF strings, and promotes the assembly of C3bBb (C3 convertase) and C3bBbC3b (C5 convertase). These linkages may help to explain enigmatic clinical problems related to thrombotic microangiopathies, including some cases of refractory thrombotic thrombocytopenic purpura (TTP), TTP associated with only mild-modest deficiencies of ADAMTS-13, the provocation (or exacerbation) of acute episodes in patients with the atypical hemolytic uremic syndrome, and thrombosis in paroxysmal nocturnal hemoglobinuria. Recent experiments have also demonstrated that complement factor H performs a dual role: participating in regulation of the AP by binding to EC-anchored ULVWF strings; and functioning as a reductase to decrease the size of soluble VWF multimers. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24967890     DOI: 10.1055/s-0034-1383547

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  14 in total

1.  Von Willebrand factor regulates complement on endothelial cells.

Authors:  Damien G Noone; Magdalena Riedl; Fred G Pluthero; Mackenzie L Bowman; M Kathryn Liszewski; Lily Lu; Yi Quan; Steve Balgobin; Reinhard Schneppenheim; Sonja Schneppenheim; Ulrich Budde; Paula James; John P Atkinson; Nades Palaniyar; Walter H A Kahr; Christoph Licht
Journal:  Kidney Int       Date:  2016-05-25       Impact factor: 10.612

2.  Endothelial dysfunction in rectal cancer patients chronically exposed to ionizing radiation.

Authors:  Tolebay Rakhypbekov; Ken Inoue; Laura Pak; Noriyuki Kawano; Nobuo Takeichi; Masaharu Hoshi; Yoshihiro Noso; Nailya Chaizhunusova; Zukhra Manambayeva; Arman Khozhayev; Maulen Molgazhdarov; Sayakhat Olzhaev; Sholpan Tokanova; Madina Madiyeva
Journal:  Radiat Environ Biophys       Date:  2017-06-16       Impact factor: 1.925

Review 3.  Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report.

Authors:  Samuel Deshayes; Nicolas Martin Silva; Valérie Chatelet; Sylvain Chantepie; Moglie Le Quintrec; François Comoz; Frank Bridoux; Marie-Agnès Dragon-Durey; Achille Aouba
Journal:  Clin Rheumatol       Date:  2018-03-07       Impact factor: 2.980

4.  The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.

Authors:  Magnus Holter Bjørkto; Andreas Barratt-Due; Ingvild Nordøy; Christina Dörje; Eivind Galteland; Andreas Lind; Abdulkarim Hilli; Pål Aukrust; Geir Mjøen
Journal:  BMC Infect Dis       Date:  2021-02-01       Impact factor: 3.090

Review 5.  The role of von Willebrand factor in thrombotic microangiopathy.

Authors:  Damien G Noone; Magdalena Riedl; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2017-07-26       Impact factor: 3.714

6.  Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors.

Authors:  Harshvardhan Upreti; Jamil Kasmani; Kathryn Dane; Evan M Braunstein; Michael B Streiff; Satish Shanbhag; Alison R Moliterno; C John Sperati; Rebecca F Gottesman; Robert A Brodsky; Thomas S Kickler; Shruti Chaturvedi
Journal:  Blood       Date:  2019-08-20       Impact factor: 22.113

7.  Decreased severity of Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS) in a child with type 1 von Willebrand disease.

Authors:  Matthew A Geramita; Johannes Hofer; James Cooper; Michael L Moritz
Journal:  BMJ Case Rep       Date:  2017-08-30

Review 8.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

9.  ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies.

Authors:  Galit Sarig
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

Review 10.  VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.

Authors:  Michael Schwameis; Christian Schörgenhofer; Alice Assinger; Margarete M Steiner; Bernd Jilma
Journal:  Thromb Haemost       Date:  2014-12-11       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.